NOKOMIS, Fla.--(BUSINESS WIRE)--Rising demand for cutting-edge stem cell therapies for diabetes could blossom into a booming market for products commercialized by Rainbow Coral Corp. (OTCBB:RBCC).
A new treatment recently described in the journal BMC Medicine uses stem cells from cord blood to re-educate a diabetic’s own T cells, helping to restart pancreatic function and reduce the need for insulin.